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21 Zusammenfassung auf Englisch
In  order  to  overcome  the  common  local  treatment  failure  of  canine  sinonasal  tumors,
integrated boost techniques were tried in the cobalt / orthovoltage era, but dismissed due to
unacceptable  early  (acute)  toxicity.  Intriguingly,  a  recent  calculation  study  of  a
simultaneously  integrated  boost  (SIB)  technique  for  sinonasal  irradiation  using  intensity-
modulated radiation therapy (IMRT) predicted theoretical feasibility. In this prospective pilot
study we applied a commonly used protocol of 10x4.2Gy to the planning target volume (PTV)
with a 20% SIB dose to the gross tumor volume (GTV). Our hypothesis expected this dose
escalation to be clinically tolerable if applied with image-guided IMRT. We included nine
dogs  diagnosed  with  sinonasal  tumors  without  local/distant  metastases.  For  treatment
planning, organs at risk were contoured according to strict anatomical guidelines. Planning
volume extensions (GTV/CTV/PTV) were standardized to minimize interplanner variability.
Treatments  were  applied  with  rigid  patient  positioning  and  verified  daily  with  image-
guidance. After radiation therapy, we set focus on early ophthalmologic complications as well
as mucosal and cutaneous toxicity. Early toxicity was evaluated at week 1, 2, 3, 8, and 12
after  radiotherapy.  Only  mild  ophthalmologic  complications  were  found.  Three  patients
(33%) had self-limiting  moderate  to  severe early toxicity  (grade 3 mucositis),  which  was
managed medically.  No patient developed ulcerations/hemorrhage/necrosis  of skin/mucosa.
The SIB protocol applied with image-guided IMRT to treat canine sinonasal tumors led to
clinically acceptable side effects. The suspected increased tumor control probability and the
risk of late toxicity with the used dose escalation of 20% has to be further investigated.
32 Zusammenfassung auf Deutsch
Um die lokale Tumorkontrolle bei Nasenhöhlentumoren des Hundes zu verbessern, wurden in
der Cobalt- / Orthovoltage-Ära spezielle Techniken mit intergrierter Boostdosis ausprobiert.
Diese  Techniken  wurden  aufgrund  inakzeptabler  akuter  Strahlentoxizität  abgelehnt.  Eine
theoretische Berechnung für die Durchführbarkeit  eines simultan intergrierten Boost (SIB)
zusammen  mit  Intensität-modulierten  Strahlentherapie  (IMRT)  sagte  eine  akzeptable
Toxizität voraus. In der hier beschriebenen prospektiven Studie wurde ein Standardprotokoll
für  Behandlung  der  Nasenhöhlentumoren  10x4.2Gy  verabreicht  und  die  Dosis  im
Tumorzentrum um 20% erhöht. Die Hypothese war, dass mit Hilfe der bildgeführte IMRT die
Dosiserhöhung  klinisch  tolerabel  ist  und  die  Tiere  keine  starken  Nebenwirkungen  haben
werden.  Es  wurden  neun  Patienten  mit  einem  diagnostizierten  Nasenhöhlentumor
eingeschlossen.  Die Behandlungen wurden mit hoher Präzision durchgeführt. Nach der RT
wurde  der  Fokus  auf  Augenkomplikationen  und  akute  Strahlentoxizität  der  Haut  und
Schleimhaut gelegt. Die akute Toxizität wurde in der Woche 1, 2, 3, 8, und 12 nach der RT
evaluiert. Nur milde Augenkomplikationen konnten festgestellt werden.  Drei Patienten (33%)
hatten selbst-limitierende mittel-  bis  hochgradige akute Toxizität  (Grad 3 Mukositis).  Das
intensivere  SIB  Protokoll,  mit  Hilfe bildgeführter  IMRT  für  Behandlung  von
Nasenhöhlentumoren beim Hund hat klinisch akzeptable akute Nebenwirkungen gezeigt. 
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OR I G I N A L A R T I C L E
A prospective pilot study on early toxicity from a
simultaneously integrated boost technique for canine
sinonasal tumours using image-guided intensity-modulated
radiation therapy
A. Soukup1 | V. Meier1 | S. Pot2 | K. Voelter2 | C. Rohrer Bley1
1Division of Radiation Oncology, Small Animal
Department, Vetsuisse Faculty, University of
Zurich, Zurich, Switzerland
2Division of Ophthalmology, Equine
Department, Vetsuisse Faculty, University of
Zurich, Zurich, Switzerland
Correspondence
Prof. C. Rohrer Bley, Division of Radiation
Oncology, Small Animal Department,
Vetsuisse Faculty, University of Zurich,
Winterthurerstrasse 260, CH-8057 Zurich,
Switzerland.
Email: crohrer@vetclinics.uzh.ch
In order to overcome the common local treatment failure of canine sinonasal tumours, integrated
boost techniques were tried in the cobalt/orthovoltage era, but dismissed because of unaccept-
able early (acute) toxicity. Intriguingly, a recent calculation study of a simultaneously integrated
boost (SIB) technique for sinonasal irradiation using intensity-modulated radiation therapy
(IMRT) predicted theoretical feasibility. In this prospective pilot study we applied a commonly
used protocol of 10 × 4.2 Gy to the planning target volume (PTV) with a 20%-SIB dose to the
gross tumour volume (GTV). Our hypothesis expected this dose escalation to be clinically tolera-
ble if applied with image-guided IMRT. We included 9 dogs diagnosed with sinonasal tumours
without local/distant metastases. For treatment planning, organs at risk were contoured accord-
ing to strict anatomical guidelines. Planning volume extensions (GTV/CTV/PTV) were standard-
ized to minimize interplanner variability. Treatments were applied with rigid patient positioning
and verified daily with image guidance. After radiation therapy, we set focus on early ophthalmo-
logic complications as well as mucosal and cutaneous toxicity. Early toxicity was evaluated at
week 1, 2, 3, 8 and 12 after radiotherapy. Only mild ophthalmologic complications were found.
Three patients (33%) had self-limiting moderate to severe early toxicity (grade 3 mucositis) which
was managed medically. No patient developed ulcerations/haemorrhage/necrosis of skin/
mucosa. The SIB protocol applied with image-guided IMRT to treat canine sinonasal tumours led
to clinically acceptable side effects. The suspected increased tumour control probability and the
risk of late toxicity with the used dose escalation of 20% has to be further investigated.
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1 | INTRODUCTION
Radiation therapy (RT) is regarded as a standard of care treatment for
canine sinonasal tumours; however, in spite of aggressive local treat-
ment a definitive cure is rarely obtained. Median survival times with
definitive-intent protocols applied in 10 to 18 fractions and total
doses of 42 to 54 Gy are typically not exceeding 10.8 to
19.7 months.1–9 The majority of patients, for example, 65% to 75%,
have to expect local failure2,3,6–10 and the progression-free interval in
regularly fractionated protocols is short, with only 29% of dogs free
of progression at 1 year.7 In order to overcome the issue of poor
local control, local treatment had been modified using post-
radiotherapy surgical exenteration, 1 to 3 fraction stereotactic proto-
cols or increased “boosts” of RT. Unfortunately, these modified treat-
ments resulted only in either comparable4,5,10 or only slightly better
outcomes,11 and in many cases also in unacceptable toxicity.1,12
The idea that with newer radiation technology a higher, more
efficient dose can safely be given is intriguing. One way to increase
radiation efficacy without delivering excessive dose to surrounding
normal tissue, are shrinking field or boost techniques. With theseAlena Soukup and Carla Rohrer Bley contributed equally to this study.
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techniques, a higher total dose is applied to the gross tumour volume
(GTV, macroscopic tumour mass), while still giving the regular high
dose to the clinical target volume (CTV, the possible area of tumour
infiltration within nasal cavity and sinuses), as well as maintaining the
fractionation effects.6,12 More than 2 decades ago, a protocol with a
boost technique was used to treat dogs with nasal tumours to a total
dose of 57 Gy, but led to excessive radiation-related toxicity. Toxicity
in early reacting tissues consisted of severe mucositis and dysphagia
and was found unacceptable in 61% of the patients. Furthermore,
median survival time was short and at least 35% of deaths were
attributed to radiation-related early (acute) side effects.12 Since then,
only one study has described the use of a boost protocol for canine
nasal tumours.13 However, this study explored molecular imaging bio-
markers and neither treatment planning details nor toxicity of radia-
tion were reported. Outcome mentioned as a secondary endpoint
with mean and median times to progression with 14.3 and
12.5 months, respectively.13 No clinical trials reporting toxicity with
boost techniques in dogs have been published since.
Especially in disease stages where the sinuses, orbit(s) and/or
cribriform plate are invaded, the surrounding organs at risk (OAR)
such as the eyes and brain can limit the available options to safely
increase the radiation dose. However, conformal avoidance of OAR
with a concurrent dramatic decrease of early and possibly late toxic-
ity is nowadays possible with advanced treatment equipment and
planning techniques, such as image-guided intensity-modulated radia-
tion therapy (IG-IMRT).7,14 Using the IMRT technique, a theoretical
planning study quantified the risk in normal tissue and possible bene-
fit in tumour control with an additional dose, added by means of a
simultaneously integrated boost (SIB).15 Boosting a selected subvo-
lume within the tumour could be an ideal way to increase the tumour
control probability (TCP) in tumours with poor local control. The TCP
curve is of sigmoidal shape, and an additional 20% boost dose of radi-
ation was predicted to lead to a large increase in tumour control in
these canine patients (increasing from the current poor 29% to 74%
at 1-year post-treatment).15 Concurrently, because of the rapid dose-
falloff outside the boost volume, reasonable patient safety in terms
of normal tissue damage was predicted for this protocol. This proto-
col has not been implemented into clinical practice so far.
With this perspective and the broader future aim to improve
local tumour control for sinonasal tumours in dogs, we clinically
implemented a simultaneously integrated boost intensity-modulated
radiation therapy (SIB-IMRT) protocol delivering a 20% increased
dose to the GTV to assess tolerability as a first step. Our hypothesis
was that the herein proposed 10-fraction protocol with a SIB used in
this prospective pilot study will maintain an acceptable risk profile in
terms of early radiation toxicity in dogs with sinonasal tumours.
2 | MATERIALS AND METHODS
2.1 | Patient and tumour characteristics
Dogs undergoing RT for malignant sinonasal neoplasia at the Division
of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Swit-
zerland, were enrolled with owner consent in this prospective pilot
study between January 2016 and March 2017. The patients are
reported under a protocol approved by the Animal Ethics Council of
the Canton of Zurich, Switzerland (Permit Number: ZH075/17). Stag-
ing workup to exclude regional and distant disease included fine-
needle aspiration (FNA) of the regional lymph node (ipsilaterally or on
the both sites), thoracic radiography and abdominal ultrasound, or
total body computed tomography (CT). For treatment planning, a pre-
and post-contrast standard CT scan of the tumour patient under gen-
eral anaesthesia was performed with a 16 MDCT unit [Brilliance CT
16-slice, Philips Health Care Ltd, Best, the Netherlands] as previously
described.16 Tumour stage was established according to the modified
Adam's staging system.17 Biopsies were taken based on CT findings
using a melon-ball forceps or via rhinoscopy. A baseline ophthalmic
examination by a board-certified veterinary ophthalmologist (S.P.:
DAVCO/DECVO or K.V.: DECVO) was performed prior to RT to
ensure the absence of active ocular disease.
2.2 | Contouring of organs at risk and target
volumes
Contouring of structures (“organs”) at risk as well as tumour-related
volumes was performed based on CT images. OAR were defined
according to an anatomy textbook18 and contoured as follows:
(1) optical structures: (a) Bulbus oculi: eyeballs were contoured with a
three-dimensional (3D)-contouring tool and diameter of the eyes was
measured (usually 2-2.2 cm). In case of loss of symmetry and/or dis-
placement of normal structures by tumour or tumour-associated
changes, contouring was performed with a free-hand tool. (b) Ocular
lens: contoured as a biconvex hyperdense structure, as distinguishable
on pre- or post-contrast CT images.19 (c) Optic nerve: defined includ-
ing the nerve sheath and contoured from the posterior aspect of the
globe, following its course through the orbit and optic canal in the
sphenoid bone. The last slice was defined as the region where the
optic nerve exits the optic canal in the sphenoid bone and enters the
optic chiasm. Delineation was performed on post-contrast studies.
(d) Retina: as previously described, the “retina-choroid-sclera com-
plex” appeared as a single hyperdense curved line, bracketed by the
rectus muscles and delineated from the posterior face of the vitreous
chamber in pre-contrast studies.20 (e) Lacrimal gland: the glands were
contoured as visualized in contrast-enhanced CT images.21 (2) Brain:
The cranial, ventral, dorsal and lateral limits were represented by the
bones forming the calvarium (os frontale, os parietale, os occipitale, os
sphenoidale and os ethmoidale). The caudal end of the foramen mag-
num was represented by the caudal limit of the structure.22 (3) Oral
cavity: (a) Palate: the mucosal lining of the hard palate was contoured
as imaged in a soft-tissue window (window level, 150 Hounsfield
units [HU]; window width, 600 HU) (b) Tongue: the volume of the
tongue was delineated as visible in the post-contrast images, caudally
up to the first slice of the appearance of the laryngeal cartilages (ker-
atohyoid cartilage). (4) Skin: it was extracted as 2 to 3 mm-thick wall
from the body surface. The volume of interest (VOI) was set from
rostral aspect of the nose to 2 cm caudally past the caudal border of
the planning target volume (PTV). In the brachycephalic breeds, the
skin contour was adapted manually. (5) Lymph nodes: they were not
included into the treatment volume.
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Tumour-related volumes were contoured as follows: the GTV
was delineated using co-registered contrast-enhanced CT images and
involved the contrast enhancing part of the tumour and the lytic
bone as imaged in bone window (window level, 400 HU; window
width, 1800 HU). The CTV accounting for subclinical microscopic dis-
ease extension was defined according to the institution's guidelines:
(1) Frontal sinus: the whole sinusoid cavity was included into the CTV
if filled with non-contrast enhancing soft tissue density (fluid or
mucus) and/or if contrast enhancing soft-tissue (GTV) was present.
(2) Nasal passages: in case of an intact nasal septum, only the
affected nasal passage including fluid or air was included, with the
contour maintained on the ipsilateral inside of the bone/septum. In
case of bilateral disease and/or nasal septum destruction, both nasal
cavities were included. In the slices where GTV was delineated, the
CTV volume was extended 1 mm into the bone/nasal septum. In case
of bone lysis, the margins were extended three-dimensionally into
the soft tissue/adjacent bone and/or limited by non-involved com-
partments. The rostral and caudal limits of the CTV were chosen to
be 2 cm from the GTV for sarcomas and 1.5 cm for carcinomas, or
were caudally limited by bony structures. In a case of tumour exten-
sion outside the nasal cavity, the margins were extended three-
dimensionally 2 cm from the GTV for sarcomas and 1.5 cm for carci-
nomas into the surrounding soft tissue and/or limited by non-
involved compartments. In our institution all treatments are applied
with rigid patient positioning devices and verified daily in an image-
guided mode (IGRT). Therefore, the margin extension CTV-PTV was a
3D extension by 2 mm to define the PTV, accounting for systematic
and random uncertainties. If the PTV extended past the body outline,
it was automatically cropped to the body contour.
2.3 | Treatment planning
For treatment planning, the Eclipse External Beam Planning system
version 10.0 (Varian Oncology Systems, Palo Alto, California) with
the AAA-algorithm (10.0.28) was used. For the treatment planning
CT, dogs were immobilized under general anaesthesia in an individu-
ally shaped vacuum cushion (BlueBag BodyFix, Elekta AB, Stockholm,
Sweden) and a custom-made bite block.23
Treatment was planned with a SIB-IMRT technique. The SIB
design intended to boost the GTV with a per-day additional dose of
20% (EQD2) above the daily 4.2 Gy to the PTV.
15 Hence, the deliv-
ered plan included 2 different dose levels: 48.3 Gy to the GTV and
42.0 Gy to the PTV. Target coverage in the GTV was planned to be
between 95% and 107% of the prescribed dose (45.9-51.7 Gy). For
the PTV the minimal target coverage was 95% of the prescribed dose
(39.9 Gy), with the maximum dose corresponding to the GTV boost
(45.9-51.7 Gy). Tissue-equivalent Superflab pliable bolus of 1 cm
thickness was placed in individual fields, if needed for adequate dose
build-up. All measures for a steep dose-fall-off outside the GTV were
taken and additional pseudo- or “helper”-structures (eg, a ring of
3 mm around the GTV) were created in order to reduce (1) conflicting
inputs on dose constraints or (2) hot spots. Maximum doses with
>110% of the prescribed doses were considered acceptable if limited
to a small volume inside the PTV. Inverse planning using a dynamic
multileaf collimator (MLC) with 5 mm leaf width was carried out with
the priority to optimize target coverage and as a secondary goal to
spare OAR. The doses to the OARs were kept as low as possible
without compromising target volume coverage, but specific dose con-
straints were not applied.
Conformity index was calculated according to the formula: CI =
V95%/TV, were V95% is the volume of 95% isodose line and TV is
the volume of the target.24 Homogeneity index was calculated
according to HI = (D2% − D98%)/D50%.
25 Because of the 2 different
target volumes with different dose, conformity and homogeneity
indexes were calculated for both GTV and PTV separately, and are
listed in section 3 as mean  SD. These calculations were performed
retroactively and the plans were not evaluated for treatment accord-
ing to these values.
Dose to OAR was reduced as much as possible during the opti-
mization process. The dose to the targets was prescribed and docu-
mented in 2 ICRU reference points, which were defined as a
representative point in the PTV on the 100% isodose line and in the
GTV on the 100% SIB prescription isodose line. Recommendations
for specification of dose were adhered to as proposed by the ICRU
report 83.25 According to the Swiss law and routine procedure in our
clinic, each treatment plan was dosimetrically verified prior to treat-
ment using an Octavius-Phantom (PTW Freiburg, Germany) and a
medical physicist approved all treatment plans.
2.4 | Treatment delivery
The definitive-intent photon treatment of 10 × 4.2 Gy + 20% SIB
(total dose: 42 Gy/SIB 48.3 Gy) was applied daily (workdays) over
2 consecutive weeks under general anaesthesia. Treatment was deliv-
ered with a 6 MV linear accelerator (Clinac iX, Varian, Palo Alto, Cali-
fornia) with high accuracy and precision in target localization because
of the abovementioned rigid patient positioning device. Daily image-
guidance (IGRT) was used for treatment verification, using kV-kV
orthogonal radiographs and/or kV cone-beam CT (CBCT). Therapy
was delivered in a dynamic IMRT mode with isocentrically planned
beams arranged in a coplanar manner.
2.5 | Permitted supportive care and assessment of
early (acute) radiation toxicity
Owing to ethical reasons, all patients were allowed to receive the
institution's standard supportive treatment for dogs undergoing RT
for sinonasal tumours. Oral treatment with NSAIDs (Meloxicam
0.1 mg/kg SID [Metacam oral suspension for dogs 1.5 mg/mL, Boeh-
ringer Ingelheim, Germany]) was initiated in all patients at the time of
diagnosis or immediately prior to the first radiation treatment. On the
day of the first radiation treatment all patients were started on topi-
cal 0.2% cyclosporine eye ointment (Optimmune MSD Animal Health,
Switzerland) and Vitamin A eye ointment (Vitamin A Blache, Baus-
ch&Lomb, Berlin, Germany), applied to both eyes, twice daily. At the
end of RT, a 3-week course of oral antibiotics (Amoxicillin clavulanate
20 mg/kg BID [Clavubactin 500/125 or 250/62.5, Graeub, Bern,
Switzerland]) was initiated to prevent bacterial translocation at sites
of radiation-induced mucosal or dermal barrier breach. In patients
who exhibited severe cutaneous side effects and/or discomfort in the
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first 3 weeks post-treatment, a switch from oral NSAID medication
to oral prednisolone 0.5 mg/kg (Prednisolone, Streuli Pharma AG,
Uznach, Switzerland) was permitted. In case of a change of medica-
tion from NSAIDs to prednisolone the patient was concurrently medi-
cated with misoprostol 3 mcg/kg (Cytotec, Pfizer GmbH, Zurich,
Switzerland) daily once for 3 consecutive days and omeprazol 1 mg/kg
(Omeprazol, Helvepharm AG, Frauenfeld, Switzerland) twice daily, for
7 consecutive days. Antibiotic and anti-inflammatory medications
were discontinued if the early side effects of radiation were healed at
the 3-week recheck. Topical eye medications were discontinued at
the 3-week recheck if Schirmer tear-test results were within our clini-
cally recommended limits (eg, >15 mm/min).26
Patients were evaluated for radiation effects on early reacting
tissues in the treatment field at the end of RT and 1, 2, 3, 8 and
12 weeks after completion of RT by a resident of the American Col-
lege of Veterinary Radiology (Radiation Oncology) (ACVR-RO, A.S.),
supported by an ACVR-RO diplomate (V.M., C.R.B.). Side effects were
scored according to Veterinary Radiation Therapy Oncology Group
(VRTOG) toxicity criteria.27 Grade 3 toxicity (confluent mucositis) was
defined as area of confluent mucositis larger than 2 cm in diameter
or ulceration, haemorrhage and necrosis. A board-certified veterinary
ophthalmologist evaluated the occurrence and severity of ocular side
effects (S.P.: DAVCO/DECVO or K.V.: DECVO). Both examiners were
unaware of the specific tumour stage, extent and laterality of the dis-
ease as well as the radiation dose distribution. Every patient received
a standardized ophthalmic examination at the defined time points.
The ophthalmic examination protocol included slit-lamp biomicro-
scopy using a hand-held slit lamp (Kowa SL-17) with ×10/16 magnifi-
cation, indirect ophthalmoscopy using a Heine Omega 200 indirect
ophthalmoscope with 20 and 28 diopter condensing lenses, Schirmer
tear-testing (STT), Fluorescein and Rose Bengal staining, tear film
break-up time (TFBUT) and corneal sensitivity estimation and appla-
nation tonometry (measuring intraocular pressure, IOP) using a cali-
brated rebound tonometer (TonoVet) (see Appendix S1, Supporting
information). A modified McDonald-Shadduck scoring system28 was
used to grade pathology in the anterior and posterior segment of the
eye (see Appendix S2).
2.6 | Statistical analysis
Data were coded in excel and analysed with SPSS Version 24 (IBM
Corp., Armonk, New York). Descriptive statistics such as absolute and
relative frequencies as well as mean (median) and SD (IQR) were
computed. The paired Wilcoxon test was used to compare the side
effects at the various control points to the pre-treatment reference.
The overall survival was defined as time from the first radiation treat-
ment until death. The progression free interval (PFI) was defined as
the time from the first radiation treatment until progression/recur-
rence of clinical signs confirmed by progressive tumour size in
CT. There was a routine CT examination scheduled at 6 months
recheck after RT. Progressive disease was defined as >20% increase
in tumour volume according to RECIST criteria in solid tumours.29 In
both analyses, the cases were censored if lost follow-up or eutha-
nized because of other cause and were derived from Kaplan-Meier
tables. Differences were considered significant at P-values <.05. The
follow-up was defined as the time from the first radiation treatment
until lost to follow-up or death.
3 | RESULTS
3.1 | Patient population
Nine dogs (3 neutered males, 4 spayed females and 2 intact females)
were included into this pilot study. The mean age at diagnosis was
10.2  2.1 years (range: 8.0-13.9 years), and the mean body weight
was 19.9  9.8 kg (range: 9.9-33.4 kg). Breeds presented involved
mixed breed dogs (n = 4), and 1 pure breed Beagle, Golden Retriever,
Poitevin, French bulldog and Pug, each.
Mild age-related changes were present, but active ocular disease
could be excluded in all dogs at the baseline ophthalmic examination
prior to radiotherapy. Histopathological tumour examination was per-
formed in 8 cases. In 1 patient, biopsy was forgone owing to a sus-
pected bleeding disorder. The patients presented with
adenocarcinoma (n = 2), esthesioneuroblastoma (n = 2), undifferen-
tiated carcinoma (n = 1), undifferentiated sarcoma (n = 1), angiofi-
broma (n = 1) and in 1 case, the biopsy was not diagnostic. Fine
needle aspirates of mandibular lymph nodes were performed bilater-
ally in 4 cases, ipsilateraly in 4 cases and were negative in all 8 cases.
In the patient with angiofibroma, lymph nodes were not sampled. All
patients were free of pulmonary metastases as staged with CT. Six
tumours were localized in the left nasal cavity, 3 were localized in the
right one. Hence, staging according to the modified Adams staging
system revealed stage 4 in 3 cases (33.3%), stage 3 in 3 cases
(33.3%), stage 2 in 2 cases (22.2%) and stage 1 in 1 case (11.1%).
Mean tumour size (GTV) at treatment start was 22.8  15.6 cm3
(range: 3.9-43.9 cm3) and the mean relative boost volume was 28.4%
of the PTVs and ranged from 13.1% to 38.3% (Table 1).
3.2 | Treatment delivery
The mean doses to target volumes were within the aspired range
with dose to GTV of 48.56  0.29 Gy, to CTV of 45.96  1.04 Gy
and to PTV of 44.97  0.88 Gy. The mean conformity index and the
mean homogeneity index to GTV was 1.55  0.25 and 0.07  0.1,
respectively. The mean conformity index and the mean homogeneity
index to PTV was 1.33  0.18 and 0.22  0.04, respectively. All tar-
get volumes are listed in Tables 1 and 2, the doses to target volumes
(including conformity and homogeneity indexes) in Table 2 and the
doses to OAR in Table 3. Superflab pliable bolus was used in 3 cases
total. In 1 case, it was used just in 1 field (0), in 1 case in 2 fields
(20 and 340) and in 1 case in 3 fields (0, 72, 288).
3.3 | Radiation toxicity
Mild to moderate early effects of radiation were seen in all cases as
provided in Table 4. These side effects were managed with the pro-
vided supportive care. One patient was switched from non-steroidal
drugs to steroid medication, 1 patient who was already on a low dose
of prednisolone therapy for unrelated reasons was maintained on ste-
roids and 1 patient received additional opioid pain medication
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tramadol-hydrochloride 2 mg/kg every 8 hours (Tramadol-Mepha,
Mepha Parma AG, Switzerland) in the second week post-RT because
of suspected pain and discomfort. None of the 3 patients with grade
3 mucosal side effects showed ulceration, mucosal bleeding or necro-
sis at any time after treatment. The most severe side effects were
observed in the oral mucosa (lip). Ocular changes as found in the
repeated ophthalmic examinations were clinically negligible. One dog
developed mild blepharitis 3 weeks after radiation because of dry
desquamation surrounding the eyes which resolved completely on
the following recheck. The values of IOP and STT are listed in
Table 5. In spite of a numerical significant decrease of IOP in the con-
tralateral eyes 1 week after radiation (P = .038), significant increase
in STT 1 week after radiation on the contralateral side (P = .018) and
significant decrease in STT 2 weeks after radiation on the ipsilateral
side (P = .028), the values remained within the reference ranges and
did not affect the patients clinically. The TFBUT values were some-
what reduced at various time points after radiation but no other signs
of tear film instability were observed. Mild peripheral corneal (max 2-
3 mm from limbus) and peripheral conjunctival pigmentation was
observed after irradiation of both eyes in 6 patients. This pigmenta-
tion remained stable or decreased at later time points in all 6 cases.
Although late effects were not a primary endpoint in this study,
the following observations were made in dogs followed longer than
12-weeks post-treatment (n = 7 ≥6 months, n = 6 ≥9 months, n = 4
TABLE 1 Target volumes and recorded highest grade and location of early toxicity
Patient GTV (cm3) CTV (cm3) PTV (cm3)
Relative boost
volume (%) Disease stage
Highest grade
of toxicity
Location of
highest toxicity
No. of weeks
post-RT
1 43.9 75.3 114.7 38.3 4 1 Mucosa 1
2 6.3 10.1 18.9 33.3 4 3 Mucosa 1
3 3.9 19.6 29.7 13.1 1 1 Mucosa, skin 1
4 43.3 82.2 114.1 38.0 2 2 Mucosa 2
5 22.9 53.9 78.4 29.2 3 3 Mucosa 0
6 12.2 65.0 92.8 13.1 4 1 Skin 1
7 20.5 56.8 83.0 24.7 2 3 Mucosa 1
8 13.8 27.0 43.2 32.0 3 2 Mucosa 2
9 38.7 86.7 115.2 33.6 3 1a Skina 1a
Abbreviations: CTV, clinical target volume; GTV, gross tumour volume; PTV, planning target volume; RT, radiation therapy.
a Evaluated by referring veterinarian.
TABLE 2 Mean volumes and doses for target volumes, dose conformity and homogeneity indices
Mean volume
(mean  SD)
(cm3)
D2%
(mean  SD)
(Gy)
D50%
(mean  SD)
(Gy)
D98%
(mean  SD)
(Gy)
Conformity index
(mean  SD)
Homogeneity index
(mean  SD)
GTV 22.83  15.60 49.79  0.37 48.56  0.29 46.42  1.40 1.55  0.25 0.07  0.1
CTV 52.96  28.01 n.a. 45.96  1.04 45.96  1.04 n.a. n.a.
PTV 76.67  37.58 49.57  0.35 44.97  0.88 39.68  1.51 1.33  0.18 0.22  0.04
Abbreviations: CTV, clinical target volume; GTV, gross tumour volume; PTV, planning target volume.
TABLE 3 Mean volumes and doses for organs at risk
Mean volume
(mean  SD) (cm3)
D2%
(mean  SD)
(Gy)
D33%
(mean  SD)
(Gy)
D50%
(mean  SD)
(Gy)
D66%
(mean  SD)
(Gy)
D98%
(mean  SD)
(Gy)
Eye ipsilateral 5.40  0.95 33.30  5.63 20.15  6.32 17.60  6.12 15.64  6.01 11.51  5.56
Eye contralateral 5.52  0.84 23.77  7.85 16.35  5.28 14.50  5.22 13.11  5.28 8.92  4.81
Lens ipsilateral 0.47  0.09 18.98  5.95 16.43  6.72 14.80  5.65 14.13  5.68 9.21  7.68
Lens contralateral 0.46  0.10 18.71  5.94 16.11  5.98 15.32  5.96 14.59  5.92 13.82  6.70
Retina ipsilateral 1.11  0.35 38.54  3.76 27.46  6.00 23.34  6.69 20.48  6.98 11.13  9.20
Retina contralateral 1.08  0.38 24.84  9.73 16.59  6.10 14.42  5.70 12.75  5.45 5.08  4.75
Lacrimal gland ipsilateral 0.18  0.09 21.17  10.13 18.56  9.58 17.80  9.22 17.06  8.83 13.60  9.24
Lacrimal gland contralateral 0.18  0.07 13.62  5.82 11.07  5.17 10.32  5.18 9.44  5.10 6.20  5.83
Optic nerve ipsilateral 0.30  0.09 36.28  5.91 31.22  8.95 28.32  10.80 24.43  13.45 5.73  8.63
Optic nerve contralateral 0.23  0.09 23.95  12.15 20.04  10.54 18.76  10.09 16.65  10.58 8.43  10.29
Brain 83.51  4.27 34.36  5.97 6.73  6.15 2.41  2.48 0.84  0.46 0.39  0.17
Tongue 80.72  35.47 19.57  5.02 11.35  4.11 9.02  3.68 6.17  3.58 0.77  0.41
Palate 6.51  2.81 44.84  4.65 38.96  6.26 36.21  7.07 30.68  12.52 14.84  12.73
Skin 60.95  22.16 36.22  5.75 16.58  6.00 10.67  4.42 6.07  3.92 0.67  0.26
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≥12 months, n = 2 ≥18 months): Cataracts were observed in 6 dogs
in both eyes at baseline examination and were classified as age-
related because of clinical appearance with multifocal punctate
nuclear and/or cortical and spoke or wedge-like cortical cataracts.30
These cataracts were stationary in 4 cases, in one case progressed
slowly on the ipsilateral side at the 2 months recheck and in one case
progressed bilaterally at later time points (6 and 9 months). A nuclear
purverulent/glasswool cataract was observed in 1 eye of 1 dog at the
baseline ophthalmologic examination and did not progress at later
time points. Furthermore, one of the dogs developed focal punctate
retinal haemorrhages on the tumour-ipsilateral side after 2 months,
which might be attributed to radiation toxicity. This change was ini-
tially very slowly progressive over time (at 3, 6 and 9 months) includ-
ing focal retinal degeneration and bullous detachment. At 6 months a
mild haemorrhage was also noted in the retina of the other eye, but
vision did not seem to be affected at any time. Surprisingly, at
12 months, the retinal changes were regressive in nature.
3.4 | Survival analysis and follow-up
The mean follow-up was 280 days, median was 289 days (95% CI:
141-420 days). One dog was euthanized because of a pre-existing
laryngeal paralysis 1.5 months after the end of RT, and 1 dog was lost
to follow-up between week 3 and week 7 (Tables 4 and 5). For
progression-free interval, the median was not reached during the
observation time. The mean PFI was 372 days (95% CI: 280-
464 days). All dogs were re-imaged with CT at the time of recurrence
or progression of clinical signs. No patient (sufficient follow-up in
7 cases) was progressive on routine CT examination 6 months after
radiation without having recurrence or progression of clinical sings
acutely. The mean survival time was 450 days (95% CI: 305-
597 days), median survival time again not reached. During the time of
observation, no severe toxicity on late reacting tissues was seen.
4 | DISCUSSION
The use of IMRT compared to the very basic 2D planning of former
decades has been shown to severely reduce frequency and severity
of toxicity to the OAR in sinonasal tumour patients.7 However, while
IMRT planning by itself can achieve a higher conformity of dose to
the PTV, the key to taking maximum advantage of this technique is
to minimize the PTV-expansion margin. The reduction of this techni-
cal, not patient-given expansion margin will effectively reduce the
(normal tissue) volume receiving high doses and is readily achieved
with accurate treatment setup such as rigid head fixation,23,31 and/or
daily image verification.7,32 The physical dose parameters (Table 2) in
our study showed a good homogeneity, close to 0 (a HI of 0 indicates
that the absorbed dose-distribution is almost homogenous).25 The
conformity indices in GTV and PTV were slightly higher than
TABLE 4 Grades of early side effects over time, according to the VRTOG acute radiation morbidity scoring scheme criteria27
VRTOG criteria Grade
End of
RT (n = 9)
1 Week post-
RT (n = 9)
2 Weeks post-
RT (n = 9)
3 Weeks post-
RT (n = 9)
8 Weeks post-
RT (n = 7)
12 Weeks post-
RT (n = 7)
Mucosa 0 6 2 2 8 7 7
1 1 4 2 1 0 0
2 1 1 5 0 0 0
3 1 2 0 0 0 0
Skin 0 6 3 2 4 4 4
1 2 5 6 5 3 3
2 1 1 1 0 0 0
3 0 0 0 0 0 0
Eye ipsilateral 0 9 9 7 7 7 7
1 0 0 2 2 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
Eye contralateral 0 9 9 8 6 7 7
1 0 0 1 3 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
TABLE 5 Values of the ophthalmological examinations (mean  SD)
Basal
examination
(n = 9)
End of RT
(n = 9)
1 Week
post-RT (n = 9)
2 Weeks
post-RT (n = 9)
3 Weeks
post-RT (n = 9)
8 Weeks
post-RT (n = 7)
12 Weeks
post-RT (n = 7)
STT (mm/min) Eye ipsilateral 24.1  3.7 23.0  5.4 26.3  5.7 21.0  2.7 22.9  3.8 19.7  3.1 20.5  3.6
Eye contralateral 22.4  5.9 22.8  5.2 26.6  5.2 22.8  3.0 23.9  6.0 20.2  2.2 20.2  4.9
IOP (mm Hg) Eye ipsilateral 14.3  5.6 10.3  2.8 10.1  3.9 12.3  5.4 13.6  4.2 14.0  3.8 16.5  2.9
Eye contralateral 14.3  5.4 12.2  3.9 10.3  3.1 12.8  6.1 14.5  3.6 15.8  4.2 15.8  3.7
Abbreviations: IOP, intraocular pressure; RT, radiation therapy; STT, Schirmer tear-testing.
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1, indicating that the irradiated volume slightly exceeds the target
volume and covers part of the healthy tissue. However, by maintain-
ing D2% and D98% for regions of high and low absorbed dose,
respectively, a CI >1 indicates a high plan normalization. Usually, a
treatment is considered in accordance with the protocol if the con-
formity index is between 1 and 2.24
However, the use of IMRT with the commonly used definitive-
intent protocols was neither expected nor found to increase tumour
control per se.7,33 An increase in local tumour control necessitates a
higher radiation dose. While one possibility of increasing the dose by
using the even more conformal proton therapy was described,34 this
treatment is hardly available for animal patients and outcome with an
escalated dose was never tested. Hence, to increase the dose to the
tumour, the suggestion and theoretical feasibility calculation to use a
SIB with IG-IMRT15 was used in this pilot study. The focus of the
herein described pilot population was to evaluate in a first step, that
the acceptable risk profile in terms of early radiation toxicity using a
20% SIB with IG-IMRT is clinically reproducible.
In prior trials delivering 42 Gy in 10 fractions with minor con-
formality, strong mucositis (grade 3) was found in 67% of dogs after
2 weeks, persisting >4 weeks in 38% of the patients.1,2 In contrast,
the same protocol applied with IG-IMRT (tomotherapy) only showed
mucositis limited to grade 1 and 2 mucositis that resolved by 2 weeks
after RT in all dogs.7 As expected, the early toxicity in our study was
slightly higher, with grade 3 confluent mucositis seen in 3/9 dogs
(33%) at the end, 1 and/or 2 weeks after RT (Table 4). However, the
differentiation between patchy and confluent mucositis is gradual
and not clearly specified in the VRTOG acute radiation morbidity
scoring scheme and our herein used definition of grade 3 confluent
mucositis (area of mucositis >2 cm in diameter) might overstate the
observed toxicity. The side effects resolved rapidly and by 3 weeks
post-RT, all side effects had healed to ≤grade 1 toxicity score. The
mean doses to the eyes were about 5% higher than described with a
non-boost protocol7 with 17.6 Gy (6.1 Gy) in the eye ipsilateral to
the tumour and 14.5 Gy (5.2 Gy) in the contralateral eye. The oph-
thalmic specialists' findings were limited to mild changes in corneal
pigmentation, IOP, tear production and TFBUT. Nevertheless, clini-
cally the eyes remained fully functional, comfortable and grossly nor-
mal to the owners as well as the attending veterinarian. The
supportive care prescribed to all patients enrolled in the study has
the potential to reduce side effects in all early reacting tissues, includ-
ing the eyes. Although late effects were not routinely evaluated in
this study, the observed cataract progression in 2 dogs and retinal
haemorrhages in 1 dog with longer follow-up periods underline the
fact that a follow-up study aimed at investigating the late effects of
this irradiation protocol is warranted. Cataract development is a typi-
cal late side effect of radiation observed already after a single dose of
2 Gy or a larger dose of 5 to 8 Gy for a prolonged or fractionated
exposure. The latent period of cataract development is several years
and it decreases with increasing dose.35 The latency of cataract
development was 6 to 12 months in dogs in one study, but the dose
to the lens in not reported specifically.36
During our study period, the observed cataracts were stable or
slowly progressive corresponding to both the suspected age-related
nature and reaction to radiation. However, the study period was too
short to evaluate these late side effects. The progressive retinal
bleeding observed clinically in 1 patient after 2 months (a late side
effect as well) has also been described in a small number of patients
(2/14) treated with 42 Gy in 10 fractions on post mortem globe eval-
uation7 and in a larger series of dogs treated with various less confor-
mal protocols and total doses of 36 to 67.5 Gy.36 In these published
cases, both clinically and histologically identified retinal haemorrhages
appeared at similar time points—3 to 6 months post-RT.36
Currently, various efforts are undertaken to overcome the poor
local tumour control in canine sinonasal tumours. The use of concur-
rent chemotherapy/radiation potentiators seems only justified if spe-
cific and selective tumour (and hence not normal tissue) sensitization
can be guaranteed. However, previous efforts with implantable low-
dose releasing cisplatinum-containing implantable sponges could not
demonstrate tumour selectivity in terms of improved local con-
trol.37,38 Similar outcomes have been reached by groups using high
conformality as applied in stereotactic techniques (stereotactic body
radiation therapy [SBRT], stereotactic radiosurgery [SRT]).4,5,11 The
use of stereotactic, severely hypofractionated radiation regimes in
general prescribe the dose to a GTV/PTV volume, which is smaller
than the commonly used GTV/CTV/PTV setup of conventional RT.4,5
While it indeed can be argued that most cases treated with more
finely fractionated protocols progress from the original GTV rather
than from the microscopic disease in the CTV1,2,7,8,15 (and hence the
volumes other than GTV are of lesser importance), future increased
local control could again shift this paradigm. In the authors' view,
canine sinonasal tumours need to remain considered as disease of
infiltrative nature and usually large extent, which do not primarily
qualify for SRT/SBRT. Furthermore, the SRT/SBRT regimes fully or
partially forgo the positive effects of fractionation, such as reoxy-
genation and potentially massively increase the risk of late toxicity,
especially when applied to larger volumes.
As predicted by the theoretical approach to estimate early toxic-
ity for a standard treatment protocol with a 20% SIB for canine sino-
nasal tumours, the early ocular, mucosal and cutaneous toxicities
observed in this prospective clinical pilot study were in a tolerable
range in terms of occurrence and severity.15 The cases selected for
this approach represent a regular cross-section of clinical presenta-
tions, as all stages of disease were included. Mean relative boost vol-
ume in our study was larger than in the theoretical planning study
(28.5% vs 9.7%,15 respectively). However, the absolute boost vol-
umes (GTV) were comparable in both studies, with our study having
smaller PTVs, probably caused by the small technical, not patient-
given expansion margin from CTV to PTV. Hence, the SIB protocol
applied with IG-IMRT at our institution led to clinically acceptable
side effects and represents a novelty in the treatment of canine sino-
nasal tumours.
We acknowledge limitations of the results presented herein
which should direct future research approaches. The case number
was limited to a small group of patients without randomized assign-
ment, 2 dogs were not definitely diagnosed and 1 dog had an uncom-
mon tumour type (angiofibroma). To assess the true levels of early
side effects and—more importantly—the potential benefit in outcome
and the relative late toxicities, future results should be collected
adhering to evidence-based principles in prospective, randomized
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clinical trials. Early (acute) toxicities even of higher grades should in
general not be considered a treatment-limiting factor, as long as they
are self-limiting and clinically manageable with symptomatic support.
However, because of the prior reported sombre outcomes due to
very strong early side effects in a study using a boost protocol,12 we
decided to perform a pilot study with a preliminary focus on early
side effects. In parallel to local tumour control, potential late toxicities
must constitute the more important focus for the future. Especially in
advanced disease settings (eg, stage IV tumours), boost protocols
might deliver high doses to parts of fraction-sensitive tissues such as
brain, causing severe late radiation toxicity.
In conclusion, our findings suggest that a 20% SIB-enhanced radi-
ation protocol can safely be applied to canine sinonasal tumours with
acceptable early side effects to ocular, mucosal and cutaneous struc-
tures. The use of SIB-enhanced radiation protocols may offer a future
route to improve the poor local tumour control in dogs with sinonasal
tumours without causing excessive discomfort to the patient or even
loss of functionality in OAR after treatment.
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